VIA
IMCR icon

Vident Investment Advisory’s Immunocore IMCR Stock Holding History

Vident Investment Advisory’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,624
Closed -$624K – 1258
2023
Q1 		$624K Sell
12,624
-156
-1% -$8.77K 0.02% 693
2022
Q4 		$729K Sell
12,780
-8,169
-39% -$460K 0.03% 586
2022
Q3 		$971K Sell
20,949
-1,963
-9% -$93.6K 0.03% 600
2022
Q2 		$854K Sell
22,912
-13,899
-38% -$451K 0.03% 674
2022
Q1 		$1.1M Buy
36,811
+6,135
+20% +$155K 0.03% 655
2021
Q4 		$1.05M Buy
+30,676
New +$1.11M 0.03% 685

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vident Investment Advisory's IMCR Position: Q2 2023 in Review

Vident Investment Advisory sold out of Immunocore (IMCR) in Q2 2023, closing a stake of 12,624 shares — an estimated $624K sold.

Vident Investment Advisory first reported a position in IMCR in Q4 2021 and held it in 6 quarters. The position peaked at $1.1M in Q1 2022. 120 funds tracked by Wall St. Rank hold IMCR as of Q2 2023.

  • Vident Investment Advisory reported no remaining Immunocore position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 12,624 Immunocore shares in Q2 2023, an estimated $624K.
  • Vident Investment Advisory first reported a position in Immunocore in Q4 2021 and held it in 6 quarters.
  • Vident Investment Advisory's Immunocore position peaked at $1.1M in Q1 2022.
  • 120 funds tracked by Wall St. Rank held Immunocore as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.